echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Sanofi dengue vaccine Dengvaxia has been approved by the European Commission

    Sanofi dengue vaccine Dengvaxia has been approved by the European Commission

    • Last Update: 2020-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    dengue fever (Dengue) is an acute insect-borne infection caused by the mosquito-borne transmission of the dengue virusClinical manifestations of high fever, headache, muscle, bone joint severe soreness, rash, bleeding tendency, lymph node swelling, white blood cell count reduction, platelet reduction, dengue fever is one of the leading causes of death among children in Southeast Asia, France'sPharmaceutical(http://giant Sanofi announced that thecompany(http://developed dengue vaccine Dengvaxia has been approved by the European Commission (EC)Dengvaxia is a four-price detoxification live vaccine for children aged 9-45 who have a record of dengue infection and are living in areas where dengue fever is endemic, and preventd dengue disease caused by all four serotypes of dengue virusin the United States,FDA(http://is prioritizing the review of Dengvaxia's Bioproduct Licensing Application (BLA) and will make a final review decision by May 1, 2019If approved, Dengvaxia would be the first and only medical prevention tool for dengue fever in the U.SmarketDengvaxia was approved by Mexico in December 2015 as the world's first approved dengue vaccine product (http:// To date, the vaccine has been approved by several dengue-endemic countries in Latin America and Asia
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.